Atypical Mole Syndrome

Atypical Mole Syndrome

National Organization for Rare Disorders, Inc.

Important

It is possible that the main title of the report Atypical Mole Syndrome is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.

Synonyms

  • B-K Mole Syndrome
  • CMM
  • Cutaneous Malignant Melanoma, Hereditary
  • DNS, Hereditary
  • Familial Atypical Mole-Malignant Melanoma Syndrome
  • FAMMM
  • HCMM
  • Malignant Melanoma, Dysplastic Nevus Type
  • Dysplastic Nevus Syndrome

Disorder Subdivisions

  • None

General Discussion

Atypical mole syndrome, also called dysplastic nevus syndrome, is a disorder of the skin characterized by the presence of many mole-like tumors (nevi). Most people have 10-20 moles over their bodies. People with this syndrome often have more than 100 moles, at least some of which are unusual (atypical) in size and structure. These moles vary in size, location, and coloring. They are usually larger than normal moles (5mm or more in diameter) and have irregular borders. Changes in the appearance of these moles must be taken seriously by patients since such changes may foreshadow the onset of cancerous disease.



Individuals with atypical mole syndrome are at greater than others for developing cancer of the skin in the form of malignant melanoma. Atypical mole syndrome is thought by some clinicians to be a precursor or forerunner of malignant melanoma. This type of cancer may spread to adjacent parts of the skin or, through the blood and lymph circulation, to other organs.

Symptoms

Symptoms of atypical mole syndrome usually start during adulthood. The disorder is characterized by the presence of a greater than normal number of moles (often more than 100), unusually large moles (greater than 5 mm in diameter), and moles that are variable in color and may combine more than one color, including tan, brown, black, red and/or pink. These moles have irregular and fuzzy or indistinct borders.



The presence of dust-like melanin (pigments found in the skin), which gives the moles their color, and abnormally large nuclei of skin cells called melanocytes, all visible under the microscope, are characteristic of dysplastic nevus syndrome. The mole-like tumors may spread to adjacent parts of the skin, or through the blood and lymph circulation, to other organs. Certain changes in the melanocyte nuclei indicate when atypical mole syndrome may be changing to malignant melanoma.

Causes

Atypical mole syndrome is inherited, but the mode of inheritance is complex and not clearly understood. It is believed to be an autosomal dominant trait in some cases, and it may involve several genes on different chromosomes. Some cases also appear to occur sporadically as the result of random mutations.



Dominant genetic disorders occur when only a single copy of an abnormal gene is necessary for the appearance of the disease. The abnormal gene can be inherited from either parent, or can be the result of a new mutation (gene change) in the affected individual. The risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy regardless of the sex of the resulting child.

Affected Populations

Symptoms of atypical mole syndrome usually appear in adulthood. Males and females are affected in equal numbers.



In the United States, the prevalence of this syndrome has been reported as 2-5% of the white population, which is about half the rate reported for Australia and New Zealand. In Sweden, about 18% of white adults are thought to show clinical signs of dysplastic nevus syndrome, but only 8% had confirmed cellular (histological) characteristics of the disorder.



While it is clear that atypical mole syndrome can lead to malignant melanoma, it is not at all clear just what the exact risk is of any single atypical mole changing into a malignant form. The risk rises as the number of moles (nevi) rises. An atypical mole syndrome patient with a family history of malignant melanoma is at greater risk than is a patient without the family history.



The disorder is more common among persons of northern European background than among Afro-Americans or Asians.

Standard Therapies

Diagnosis

Diagnosis of atypical mole syndrome is reasonably obvious if, on physical examination, an unusually large number of moles are found on the patient's arms, trunk and/or head. Parts of the body regularly exposed to sunlight are especially vulnerable. The patient's history will show that some of the moles will be peculiarly colored, or that the color has changed over time. Other moles will have grown in size and/or changed texture.



As soon as possible after one or more moles undergo changes, a biopsy is essential in order to determine if any of the cells that make up the mole have become cancerous.



Treatment

Treatment is primarily a matter of preventive measures, such as staying out of the sun during the hottest time of the day, to lower the risk for malignant melanoma, and of regular self-examination and in-office examination so that any possible malignancies may be detected as early as possible and treated appropriately. It has been well documented that early detection and treatment of malignant melanoma improve the likelihood of successful treatment.



Affected individuals are advised to avoid direct sunlight and use a protective sunscreen. Other preventive measures include wearing a wide-brimmed hat, sunglasses, and protective clothing when in the sun, avoiding tanning machines, and protecting children (and especially infants) from excessive exposure to the sun.



It is not necessary, or even advised, to remove multiple atypical moles beforehand in an attempt to prevent development of malignant melanoma. However, any change in such a mole should be reported to one's physician immediately.

Investigational Therapies

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.



For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:



Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov



Further information on clinical trials, especially those sponsored by pharmaceutical companies, is available at: www.centerwatch.com

References

TEXTBOOKS

Beers MH, Berkow R, eds. The Merck Manual, 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:839.



Berkow R., ed. The Merck Manual-Home Edition.2nd ed. Whitehouse Station, NJ: Merck Research Laboratories; 2003:989-90.



Champion RH, Burton JL, Ebling FJG, eds. Textbook of Dermatology. 5th ed. Blackwell Scientific Publications. London, UK; 1992:1543-45.



Habif TP. ed. Clinical Dermatology. 2nd ed. The C.V. Mosby Company. St. Louis, MO; 1990:561-63.



REVIEW ARTICLES

Roesch A, Landthaler M, Vogt T. [The dysplastic nevus. Separate entity, melanoma precursor or diagnostic dilemma? Hautarzt. 2003;54:871-83.



Bauer J, Garbe C. Acquired melanocytic nevi as a risk factor for melanoma development. A comprehensive review of the epidemiological data. Pigment Cell Res. 2003;16:297-306.



Hussein MR, Wood GS. Molecular aspects of melanocytic dysplastic nevi. Recent Results Cancer Res. 2002;160:71-80.



Salopek TG. The dilemma of the dysplastic nevus. Dermatol Clin. 2002;20:617-28.



JOURNAL ARTICLES

Oliveria SA, ChauD, Christos PJ, et al. Diagnostic accuracy in performing skin self-examination and the impact of photography. Arch Dermatol. 2004;140:57-62.



Czajkowski R, Placek W, Drewa G, et al. FAMMM syndrome: pathogenesis and management. Dermatol Surg. 2004;30(2 Pt 2):291-96.



Robinson JK, Nickoloff BJ. Digital epiluminescence microscopy monitoring of high-risk patients. Arch Dermatol. 2004;140:49-56.



Branstrom R, Hedblad MA, Krakau I, et al. Reasons to seek medical attention for a skin check-up: the layman's perspective. Eur J Public Helath. 2003;13:294-98.



Jamora MJ, Wainwright BD, Meehan SA, et al. Improved identification of potentially dangerous pigmented skin lesions by computerized image analysis. Arch Dermatol. 2003;139:195-98.



Masci P, Borden EC. Malignant melanoma: treatments emerging, but early detection is still key. Cleve Clin J Med. 2002;69:529, 533-34, 536-38.



Zaludek I, Hafmann-Wellenhof R, Cerroni L, et al. White dysplastic melanocytic naevi. Lancet. 2002;359:1999-2000.



Tripp JM, Kopf AW, Marghoob AA, et al. Management of dysplastic nevi: a survey of fellows of the American Academy of Dermatology. J Am Acad Dermatol. 2002;46:674-82.



Salopek TG, Kopf AW, Stefanato CM, et al. Differentiation of atypical moles (dysplastic nevi) from early melanomas by dermoscopy. Dermatol Clin. 2001;19:337-45.



Hussein MR, Sun M, Tuthill RJ, et al. Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi. J Cutan Pathol. 2001;28:343-50.



FROM THE INTERNET

Dysplastic (Atypical) Nevus. BC Cancer Agency. ©2004. 2pp.

www.bccancer.bc.ca/HPI/CME/SkinCancer/CMESkinCancer/Readings/EarlyDiagnosis/DysplasticNevus.htm



Leavitt SA, Salasche S. Dysplastic Nevi. University of Arizona Health Science Center. nd. 3pp.

www.ahsc.arizona.edu/opa/crnap/nevi.html



Weber PJ. Atypical Mole = Dysplastic Nevus. ©2003. 15pp.

www.skincancerinfo.com/sectionf/atypicalmole.html



The Dermatology Network. Dysplastic Nevi & Malignant Melanoma. nd. 2pp.

www.dermnetwork.org/nevi&melanoma-1.htm



Marghoob AA. The dangers of atypical mole (dysplastic nevus) syndrome. 1999. 11pp

www.postgradmed.com/issues/1999/06_99/marghoob.htm

Resources

Nevus Network

PO Box 305

West Salem, NC 44287

USA

Tel: (419)853-4525

Fax: (405)377-3403

Email: info@nevusnetwork.org

Internet: http://www.nevusnetwork.org/



Skin Cancer Foundation

149 Madison Avenue

Suite 901

New York, NY 10016

Tel: (212)725-5176

Fax: (212)725-5751

Tel: (800)754-6490

Email: info@skincancer.org

Internet: http://www.skincancer.org



American Cancer Society, Inc.

250 Williams NW St

Ste 6000

Atlanta, GA 30303

USA

Tel: (404)320-3333

Tel: (800)227-2345

TDD: (866)228-4327

Internet: http://www.cancer.org



Rare Cancer Alliance

1649 North Pacana Way

Green Valley, AZ 85614

USA

Internet: http://www.rare-cancer.org



Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Internet: http://rarediseases.info.nih.gov/GARD/



Friends of Cancer Research

1800 M Street NW

Suite 1050 South

Washington, DC 22202

Tel: (202)944-6700

Email: info@focr.org

Internet: http://www.focr.org



Cancer Support Community

1050 17th St NW Suite 500

Washington, DC 20036

Tel: (202)659-9709

Fax: (202)974-7999

Tel: (888)793-9355

Internet: http://www.cancersupportcommunity.org/



Lance Armstrong Foundation

2201 E. Sixth Street

Austin, TX 78702

Tel: (512)236-8820

Fax: (512)236-8482

Tel: (877)236-8820

Email: media@livestrong.org

Internet: http://www.livestrong.org



For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use . How this information was developed to help you make better health decisions.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.